1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. GLUT

GLUT

Glucose transporter

GLUTs (Glucose transporters ) are proteins comprising 12 membrane-spanning regions. GLUTs transport glucose across the plasma membrane by means of a facilitated diffusion mechanism.

GLUT1 (SLC2A1), a uniporter protein, facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT2 (SLC2A2) is a transmembrane carrier protein that enables protein facilitated glucose movement across cell membranes. GLUT3 (SLC2A3), mainly present in the brain, has high affinity for glucose. GLUT3 facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT4 (SLC2A4) is found in the heart, skeletal muscle, adipose tissue, and brain. GLUT4 is an insulin-responsive glucose transporter.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139066
    Punicic acid
    Agonist ≥98.0%
    Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways.
    Punicic acid
  • HY-149276
    SLC26A3-IN-2
    ≥98.0%
    SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
    SLC26A3-IN-2
  • HY-139047
    SW157765
    Inhibitor 98.08%
    SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs.
    SW157765
  • HY-146980
    GLUT4-IN-2
    Inhibitor 99.90%
    GLUT4-IN-2 is a potent and selective GLUT4 inhibitor with IC50s of 11.4 µM and 6.8 µM for GLUT1 and GLUT4, respectively. GLUT4-IN-2 induces cell apoptosis and cell cycle arrest at G0/G1phase. GLUT4-IN-2 shows potent antitumor activity.
    GLUT4-IN-2
  • HY-144305
    KPH2f
    Inhibitor 98.05%
    KPH2f is a safe, orally active, and effective dual URAT1/GLUT9 inhibitor with IC50s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC50=32.14 and 26.74 μM).
    KPH2f
  • HY-N4095
    Brevifolincarboxylic acid
    99.90%
    Brevifolincarboxylic acid is an α-glucosidase inhibitor with an IC50 of 323.46 μM. Brevifolincarboxylic acid has inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarboxylic acid scavenges ROS. Brevifolincarboxylic acid restores glucose uptake activity of myotubes. Brevifolincarbacid can be used in diabetes research.
    Brevifolincarboxylic acid
  • HY-128574
    GLUT4 activator 1
    Activator 99.71%
    GLUT4 activator 1 (Compound 26b) is a potent glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM.
    GLUT4 activator 1
  • HY-W110888
    Brilliant Yellow
    Inhibitor
    Brilliant Yellow, a diazo-containing sulfonic aci, is also a potent VGLUT-specific inhibitor. Brilliant Yellow is membrane-impermeable. However, there are some Brilliant Yellow analogs with low cytotoxicity and cell penetration. Brilliant Yellow analogs work on glutamatergic transmission in hippocampal neurons.
    Brilliant Yellow
  • HY-153612
    MMV009085
    Inhibitor
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7).
    MMV009085
  • HY-N7433
    4,6-O-Ethylidene-α-D-glucose
    Inhibitor ≥98.0%
    4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport.
    4,6-O-Ethylidene-α-D-glucose
  • HY-148315
    GLUT1-IN-2
    Inhibitor 99.27%
    GLUT1-IN-2 (compound 17) is a GLUT1 inhibitor with an IC50 value of 12 μM. GLUT1-IN-2 shows inhibitory effect to Plasmodium falciparum hexose transporter PfHT with an IC50 value of 13 μM. GLUT1-IN-2 can be used for the research of infection.
    GLUT1-IN-2
  • HY-108935
    Lavendustin B
    Inhibitor 98.02%
    Lavendustin B is an inhibitor of HIV-1 integrase interaction with LEDGF/p75 with an IC50 of 94.07 μM. Lavendustin B is an ATP-competitive GLUT1 inhibitor with a Ki of 15 μM. Lavendustin B is also a weak inhibitor of tyrosine kinases.
    Lavendustin B
  • HY-N6935
    Sennidin B
    Activator 99.25%
    Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .
    Sennidin B
  • HY-P4588
    (Glu17,21,24)-Osteocalcin (1-49) (human)
    (Glu17,21,24)-Osteocalcin (1-49) (human) is a bone-specific protein involved in bone formation and glucose metabolism.
    (Glu17,21,24)-Osteocalcin (1-49) (human)
  • HY-N0142R
    Phloretin (Standard)
    Inhibitor
    Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
    Phloretin (Standard)
  • HY-128361
    SLC26A3-IN-3
    Inhibitor
    SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC50: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis.
    SLC26A3-IN-3
  • HY-158056
    URAT1/GLUT9-IN-1
    Inhibitor
    URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research.
    URAT1/GLUT9-IN-1
  • HY-163726
    GLUT1/EGFR-IN-1
    Inhibitor 99.75%
    GLUT1/EGFR-IN-1 (compound H) is a potent inhibitor of GLUT1 and EGFR. GLUT1/EGFR-IN-1 can simultaneously act on the EGFR tyrosine kinase ATP-binding site and inhibit GLUT1-mediated energy metabolism, resulting in reductions in ATP, MMP, intra-cellular lactic acid, and EGFR nuclear transfer. GLUT1/EGFR-IN-1 can be used for nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC) research.
    GLUT1/EGFR-IN-1
  • HY-155093
    GLUT1-IN-3
    Inhibitor
    GLUT1-IN-3 (Compd 4b), an investigational compound associated with type 1 glucose transporter deficiency syndrome, potently suppresses seizures.
    GLUT1-IN-3
  • HY-149802
    SLC26A3-IN-1
    SLC26A3-IN-1 is an inhibitor of anion exchanger protein SLC26A3 (IC50=340 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
    SLC26A3-IN-1
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.